Kent Meningitis B Outbreak: Vaccine Expanded to Year 11 Pupils

Health officials are expanding the meningitis B vaccination program to include Year 11 pupils at schools in Kent affected by a recent outbreak. The move comes as confirmed cases of the illness have slightly decreased, though concerns remain about potential further spread. This expansion aims to provide a precautionary layer of protection for students, building on the vaccination efforts already underway at the University of Kent.

Kent Outbreak: Current Status and Affected Groups

As of Monday afternoon, 20 cases of meningitis B have been confirmed in Kent, with an additional three still under investigation, bringing the total to 23. This represents a decrease from the 29 cases (20 confirmed, 9 under investigation) reported on Sunday. Vaccinations for students at the University of Kent began on Wednesday, March 18th. Health Secretary Wes Streeting, during a visit to the campus the following day, announced the planned expansion of the program to include sixth form pupils at four schools with known or suspected cases of menB. Now, that expansion includes Year 11 pupils at those schools, according to the UK Health Security Agency (UKHSA).

The majority of those affected are students, with a median age of 19. Yet, five individuals who contracted the illness are not currently enrolled as students. A significant proportion – 87% – of those who became unwell had visited Club Chemistry in Canterbury between March 5th and 7th. The three cases not linked to the nightclub are all University of Kent students residing in halls of residence with connections to those who did attend the venue. The earliest reported case emerged on March 9th, with the most recent on March 16th, and the peak of the outbreak occurred on March 13th.

Understanding Meningitis B and the Current Strain

Meningitis B is caused by the bacterium Neisseria meningitidis serogroup B. It’s a serious infection that can lead to severe illness and, in some cases, death. Symptoms can include fever, headache, stiff neck, vomiting, and sensitivity to light. The NHS website provides comprehensive information on the signs and symptoms of meningitis and what to do if you suspect someone is affected.

The strain responsible for the Kent outbreak belongs to a group of bacteria known as group B meningococci, and features a recently emerged subtype that has been present in England since 2020. However, initial analysis suggests the genome of the bacteria exhibits “multiple potentially significant genetic differences” compared to closely related strains. These differences are currently being investigated to determine their potential impact on the bacteria’s behavior and spread.

Reassurance on Vaccine Effectiveness and Treatment

Crucially, analysis by the UKHSA indicates that the circulating strain remains susceptible to both antibiotics and the MenB vaccine (4CMenB). Professor Robin May, Chief Scientific Officer at UKHSA, stated that this preliminary analysis provides “strong reassurance” that existing vaccinations and antibiotic treatments will be effective against this particular strain. Bloomberg reports on the UKHSA’s assessment of the outbreak and vaccine efficacy.

All patients in the Kent outbreak have required hospital admission, with nine admitted to intensive care, four of whom remain there. Tragically, two University of Kent students have died: 18-year-old Juliette Kenny, described by her family as “fit, healthy and strong,” and another student whose identity has not been publicly released.

Laboratory Investigations and Ongoing Surveillance

The UKHSA is conducting intensive laboratory investigations to understand how the spread of the outbreak may have been influenced by the bacterial strain, social factors, environmental conditions, and population immunity levels. This involves detailed genomic sequencing and analysis of the bacteria to identify any unique characteristics that may be contributing to its spread. This perform is being done in collaboration with the wider research community.

Public health surveillance systems are continuously monitoring for new cases of meningitis B, not only in Kent but across the UK. These systems rely on reports from hospitals, laboratories, and healthcare professionals to detect and respond to outbreaks quickly. As reported by the BBC, the initial fall in cases is being closely monitored.

What Happens Next: Continued Monitoring and Potential Adjustments

The UKHSA will continue to closely monitor the situation in Kent and assess the impact of the expanded vaccination program. Further laboratory investigations will provide a more detailed understanding of the bacterial strain and its characteristics. The agency will similarly evaluate the effectiveness of the vaccination campaign and make adjustments as needed. This includes reviewing data on vaccine coverage, the incidence of new cases, and the severity of illness among vaccinated individuals. The findings from these investigations will inform future guidance and recommendations on meningitis B vaccination.

Individuals experiencing symptoms of meningitis should seek immediate medical attention. It’s also important to stay informed about the outbreak and follow any public health advice issued by the UKHSA and local authorities. Parents and guardians of students in affected schools should be particularly vigilant and monitor their children for any signs of illness.